左旋多巴和脱羧酶抑制剂诱发的痛风。
Gout induced by L-dopa and decarboxylase inhibitors.
作者信息
Calne D B, Fermaglich J
出版信息
Postgrad Med J. 1976 Apr;52(606):232-3. doi: 10.1136/pgmj.52.606.232.
Abstract
Two cases of clinical gout are reported in parkinsonian patients receiving L-dopa in combination with a decarboxylase inhibitor. Blockade of decarboxylation leads to major changes in the pattern of L-dopa metabolites. It is suggested that hyperuricaemia may result from accumulation of L-dopa itself or a transaminated product.
摘要
报告了两例接受左旋多巴联合脱羧酶抑制剂治疗的帕金森病患者出现临床痛风的病例。脱羧作用的阻断导致左旋多巴代谢产物模式发生重大变化。有人认为高尿酸血症可能是由左旋多巴本身或一种转氨产物的积累所致。
相似文献
1
Gout induced by L-dopa and decarboxylase inhibitors.左旋多巴和脱羧酶抑制剂诱发的痛风。
Postgrad Med J. 1976 Apr;52(606):232-3. doi: 10.1136/pgmj.52.606.232.
2
Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.左旋多巴与脱羧酶抑制剂：其临床药理学及在帕金森病治疗中的应用综述
Drugs. 1976;11(5):329-77. doi: 10.2165/00003495-197611050-00001.
3
[CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].[CB 154治疗帕金森病。与左旋多巴和脱羧酶抑制剂联合使用的结果]
Acta Neurol (Napoli). 1976 Jul-Aug;31(4):479-48.
4
[Somatosensory evoked potentials in patients with parkinsonism during L-dopa decarboxylase inhibitor treatment].[帕金森病患者在左旋多巴脱羧酶抑制剂治疗期间的体感诱发电位]
Neurol Neurochir Pol. 1977 Jan-Feb;11(1):73-80.
5
[Treatment of Parkinson's syndromes by a combination of levodopa with decarboxylase inhibitors].左旋多巴与脱羧酶抑制剂联合治疗帕金森综合征
Cesk Neurol Neurochir. 1975 Dec;38(6):327-32.
6
Treating parkinsonism with L-dopa and carboxylase inhibitor.
Mod Med Asia. 1977 Sep;13(9):23-5.
7
Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.用外周脱羧酶抑制剂卡比多巴和左旋多巴治疗帕金森病。
Med Ann Dist Columbia. 1974 Dec;43(12):587-91.
8
Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation.
Acta Neurol Scand. 1977 Dec;56(6):508-24. doi: 10.1111/j.1600-0404.1977.tb01456.x.
9
The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Treatment with levodopa and decarboxylase inhibitor.
Arch Neurol. 1977 Apr;34(4):228-32. doi: 10.1001/archneur.1977.00500160042007.
10
[Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].左旋多巴与多巴脱羧酶抑制剂治疗帕金森病
Neurol Neurocir Psiquiatr. 1976;17(4):293-300.
引用本文的文献
1
Association of polymorphisms in genes involved in the dopaminergic pathway with blood pressure and uric acid levels in Chinese females.中国女性多巴胺能通路相关基因多态性与血压和尿酸水平的关系。
J Neural Transm (Vienna). 2010 Dec;117(12):1371-6. doi: 10.1007/s00702-010-0492-6. Epub 2010 Oct 8.
本文引用的文献
1
[Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].
Presse Med (1893). 1971 Jan 16;79(3):91-2.
2
False rise in serum uric acid after L-dopa.
N Engl J Med. 1969 Dec 25;281(26):1489-90.
3
Gout while receiving levodopa for Parkinsonism.帕金森病患者在接受左旋多巴治疗时出现痛风。
JAMA. 1972 Jan;219(1):55-7.
4
Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.
Mayo Clin Proc. 1972 Jun;47(6):389-95.
5
Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition.
Nature. 1974 Feb 8;247(5440):364-6. doi: 10.1038/247364b0.
6
Parkinsonism treated with 3-O-methyldopa.
Clin Pharmacol Ther. 1973 May-Jun;14(3):386-9. doi: 10.1002/cpt1973143386.
7
Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase.
J Neurol Sci. 1972 Sep;17(1):45-51. doi: 10.1016/0022-510x(72)90021-4.
Zotero 插件